We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Assessment of myopic rebound effect after discontinuation of treatment with 0.01% atropine eye drops in Japanese school-age children.
- Authors
Hieda, Osamu; Hiraoka, Takahiro; Fujikado, Takashi; Ishiko, Satoshi; Hasebe, Satoshi; Torii, Hidemasa; Takahashi, Hiroshi; Tanaka, Shiro; Kinoshita, Shigeru; Nakamura, Yo; Sotozono, Chie; Oshika, Tetsuro; Morimoto, Takeshi; Nishida, Kohji; Nishikawa, Noriko; Song, Young-Seok; Tokutake, Tomoki; Nishi, Yasuyo; Shigeno, Yuta; Kurihara, Toshihide
- Abstract
Purpose: Having previously demonstrated the efficacy of 0.01% atropine eye drops for inhibiting progression of childhood myopia, we conducted additional analyses to assess post-treatment changes in myopia progression. Study design: Analysis of follow-up data from a previously reported randomized controlled trial Methods: A mixed-effects model was used to compare intergroup changes in spherical equivalent (SE) and axial length (AL) at 1 month and 12 months after discontinuation of 2-year treatment with atropine or placebo in 167 school-age children. Results: Follow-up measurements were available for 149 participants at 1 month after discontinuation of treatment and for 51 participants at 12 months after discontinuation. At 1 month post-treatment, differences between the atropine and placebo groups in least squares (LS) mean changes in SE and AL, respectively, from 24 months were −0.06 diopters (D) (95% CI: −0.21, 0.08; P =.39) and 0.02 mm (95% CI: −0.05, 0.08; P =.60). At 12 months post-treatment, intergroup differences (atropine vs placebo) in LS mean changes in SE and AL, respectively, were −0.13 D (95% CI: −0.35, 0.10; P =.26) and −0.02 mm (95% CI: −0.12, 0.09; P =.75). LS mean changes in SE and AL from treatment discontinuation did not differ between the groups at 1 or 12 months post-treatment. Conclusion: Axial elongation was significantly less in the atropine group than in the placebo group. The suppression effect obtained at 2 years was maintained after 12 months. The absence of intergroup differences in myopia progression since treatment cessation suggests that myopic rebound did not occur.
- Subjects
TERMINATION of treatment; EYE drops; ATROPINE; RANDOMIZED controlled trials
- Publication
Japanese Journal of Ophthalmology, 2023, Vol 67, Issue 5, p602
- ISSN
0021-5155
- Publication type
Article
- DOI
10.1007/s10384-023-01012-8